Apollo Hospitals has announced plans to establish a 100-bed Comprehensive Oncology Centre at Gurugram, which will integrate the next generation Proton Therapy System.
The centre will form part of Phase 2 expansion of Apollo’s upcoming 500-bed hospital in Gurugram. The Phase 1 development is scheduled to be commissioned by Q4 FY25 / Q1 FY26, with the Proton and Integrated Cancer Centre targeted for completion over the next four years.
This facility will be Apollo’s third Proton Therapy installation in India. The first was its flagship Proton Centre in Chennai, the first of its kind in South Asia and the Middle East, which has treated more than 2,500 patients from 147 countries. The second installation is underway at Jubilee Hills, Hyderabad, within a dedicated 70-bed cancer centre. The Gurugram facility will add to Apollo’s integrated pan-India oncology programme.
Proton therapy is used primarily for treating tumours in paediatric cases, head and neck cancers, central nervous system tumours, bone and soft tissue cancers, prostate cancer, and a range of other malignancies.
According to studies, the global cancer burden is projected to rise to 21.4 million incident cases by 2030. A study published in The Lancet Regional Health stated that India ranks third worldwide, after China and the United States, contributing 7.5 per cent of new cancer cases, with incidences expected to reach 1.5 million this year.
The Gurugram Cancer Centre will include:
- Next generation Proton Therapy for precision radiation treatment.
- Advanced multi-system robotics for minimally invasive cancer surgeries.
- High-end linear accelerators for image-guided and adaptive radiotherapy.
- Immunotherapy and targeted therapies for customised treatment protocols.
- Personalised and genomics-driven medicine to align treatment with individual biology.
- Bone marrow transplant and CAR T-cell therapies for patients with blood disorders and complex malignancies.
Apollo has outlined oncology growth plans across its five key markets—Chennai, Hyderabad, Mumbai, Bengaluru and NCR—with further investments planned in other cities. These centres will anchor Apollo’s nationwide oncology programme combining technology, global protocols and multidisciplinary expertise. Apollo aims to double the scale of its oncology business to over ₹5,000 crore in three to four years.
Dr Prathap C Reddy, Founder-Chairman, Apollo Hospitals Enterprise, said, “At Apollo, we are driven by an unyielding passion for excellence in healthcare. Our commitment is to ensure that India remains at the forefront of medical innovation, providing patients with access to the world’s most advanced treatments. The addition of next generation proton therapy to our Apollo Proton Cancer Centres further solidifies our position as a global leader in Proton Therapy. This next generation technology will allow us to achieve superior clinical outcomes and significantly improve the quality of life for cancer patients in India and beyond.”
Dr Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise added, “Cancer care is evolving rapidly, and at Apollo, we remain steadfast in our mission to stay ahead of this evolution. The introduction of the next generation proton therapy is a significant leap towards personalised, precise, and highly effective treatment for cancer patients. Through this project we will facilitate knowledge-sharing and training for oncologists, enabling the widespread adoption of advanced treatment modalities across the region.”